Zorko, Nicholas A. http://orcid.org/0000-0001-7021-968X
Makovec, Allison http://orcid.org/0009-0008-2487-9079
Elliott, Andrew
Kellen, Samuel
Lozada, John R.
Arafa, Ali T.
Felices, Martin
Shackelford, Madison
Barata, Pedro
Zakharia, Yousef http://orcid.org/0000-0001-9480-2626
Narayan, Vivek http://orcid.org/0000-0002-8205-738X
Stein, Mark N.
Zarrabi, Kevin K.
Patniak, Akash
Bilen, Mehmet A.
Radovich, Milan
Sledge, George
El-Deiry, Wafik S.
Heath, Elisabeth I. http://orcid.org/0000-0003-1381-2713
Hoon, Dave S. B.
Nabhan, Chadi
Miller, Jeffrey S.
Hwang, Justin H.
Antonarakis, Emmanuel S. http://orcid.org/0000-0003-0031-9655
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-22-1-0242, W81XWH2110255, W81XWH-20-1-0659, W81XWH-20-1-0535, W81XWH-21-1-0255, W81XWH-20-1-0341, W81XWH2110255, W81XWH-20-1-0659)
Prostate Cancer Foundation (22YOUN08)
U.S. Department of Health & Human Services | National Institutes of Health (T32 GM008244, T32 GM008244)
American Society of Hematology (Medical Student Minority Award)
Randy Shaver Cancer Research and Community Fund
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA283892, P01 CA111412, P30 CA077598, P01 CA111412, P01 CA065493, R35 CA283892, P01 CA065493, P01 CA111412, P30 CA077598, P30 CA077598)
Article History
Received: 8 October 2023
Revised: 17 January 2024
Accepted: 22 January 2024
First Online: 28 February 2024
Competing interests
: Nicholas Zorko reports paid travel from Caris Life Sciences and Telix Pharmaceuticals. Andrew Elliott, Milan Radovich, George Sledge, and Chadhi Nabhan are employees of Caris Life Sciences. Yousef Zakharia reports personal fees (Advisory Board) from Bristol Myers Squibb, Janssen, Eisai, Exelixis, Genzyme Corporation, Pfizer. Vivek Narayan reports grants from Janssen, Merck, Regeneron, Pfizer, and Bristol Myers Squibb; and personal fees from Janssen, Merck, Regeneron, Pfizer, Exelixis, AstraZeneca, Myovant, and Bristol Myers Squibb. Mark N. Stein serves in a consulting or advisory role for Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor and receives research funding from Advaxis (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals; Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Regeneron (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst). Kevin K. Zarrabi reports advising/consulting fees from Exelixis, Esai. Akash Patniak reports Consultancy/Advisory Board for Janssen, Exelixis, Jounce Therapeutics, BostonGene. Grant/Research support from BMS. Clinical Trial Support from BMS, Clovis Oncology, Progenics, Janssen, Laekna, Astrazeneca, Xencor, and Zenith. Honoraria from Exelixis, Janssen, Roche, Clovis Oncology, Merck, Prime, Curio. M.A. Bilen has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi and has received grants to his institution from Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Genome & Company, AAA, Peloton Therapeutics, and Pfizer for work performed as outside of the current study. Elisabeth I. Heath – Advisory/Consulting: Astellas, AstraZeneca, Bayer, Sanofi; Steering Committee: Janssen; Honararia/Paid Travel: Astellas, Bayer, Caris, Sanofi, Seattle Genetics; Speaker’s Bureau: Sanofi; Research Support: Astellas, Arvinas, AstraZeneca, Bayer, BioXcel, Bristol-Myers Squibb, Calibr, Calithera, Caris, Corcept, Corvis, Daiichi Sankyo, Eisai, Exelixis, Five Prime, Fortis, GlaxoSmithKline, Gilead Sciences, Harpoon, Hoffman-La Roche, Infinity, iTeos, Janssen, Merck Sharp & Dohme, Merck, Mirati, Modra, Novartis, Oncolys, Peloton, Pfizer, Pharmacyclics, POINT Biopharma, Seattle Genetics. Emmanuel S. Antonarakis reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, Novartis, Merck, Pfizer, AstraZeneca, Clovis, and Orion; and personal fees from Astellas, Amgen, Blue Earth, Exact Sciences, Invitae, Eli Lilly, and Foundation Medicine; in addition, he has an issued patent for an AR-V7 biomarker technology that is licensed to Qiagen. The remaining authors have no relevant discolsures or conflicts of interest to declare.